Elevated transferrin and serum iron (~1.2 fold higher) have been reported in OCP females, from the first to the third generation of OCP pills (Casabellata et al., 2007), with females on these OCPs more likely to have transferrin saturation levels >45% and be considered at risk of hemochromatosis (McKnight et al., 1980). This evidence concerns the gene TF and hemochromatosis type 1.